Supplied as a white to off-white crystalline powder with a lot-controlled certificate of analysis, (S)-(-)-Indoline-2-carboxylic acid Pharma Grade is released under cGMP controls for tablet, capsule, granule, oral liquid, and injectable manufacturing. The compound has the empirical formula C9H9NO2, a relative molecular mass of 163.17 g/mol, CAS 79815-20-6, and one stereogenic centre at C-2. The (S)-configured acid is controlled as a single enantiomer and is not interchangeable with racemic indoline-2-carboxylic acid used in non-chiral synthesis or with the (R)-(+)-enantiomer. The product is supplied under a model designation that separates oral-grade and injectable-grade lot release; injectable-grade lots are additionally controlled for bioburden and bacterial endotoxins. Typical release documentation includes appearance, specific optical rotation by Ph.Eur. 2.2.7 or USP 781, chromatographic purity by USP 621, water content by USP 921, residue on ignition by USP 281, residual solvents by USP 467 aligned with ICH Q3C, elemental impurities by ICH Q3D with USP 232 and USP 233, and microbial enumeration by USP 61 and USP 62. For injectable use, the same lot is additionally tested for bacterial endotoxins by USP 85 and for subvisible particulate matter after reconstitution or dilution by USP 788. The free acid has pH-dependent solubility; injectable processing often employs in situ salt formation or a pH-adjusted vehicle, but the exact solubility profile must be confirmed in the selected formulation because published data for every vehicle composition is limited.

Chiral Purity and Related Substance Control Across Oral Granulation

Enantiomeric purity is the principal release attribute because the (R)-(+)-enantiomer introduces a different stereochemical profile and must be limited as a specified chiral impurity. Chiral HPLC with a polysaccharide-based stationary phase is used; the R-enantiomer acceptance limit is set at or below the lower of the ICH Q3A identification threshold and the dose-based limit for the intended daily dose. For a drug substance with a maximum daily dose below 2 g/day, the ICH Q3A identification threshold is 0.1% and the qualification threshold is 0.15%; the batch-release specification should be set accordingly and may be lower if the dose is higher or if the toxicological assessment supports a tighter limit. Racemization risk is evaluated under forced degradation in the wet granulation fluid because high-temperature drying can shift the chiral balance when residual water and alkaline excipients coexist. The drying endpoint for a granulated intermediate is therefore not assigned from loss-on-drying data alone; enantiomeric purity must be remeasured after drying. For direct compression, the absence of water reduces the racemization pathway, but the blend still requires chiral assay after compaction to verify that shear heating during tableting does not exceed the stability boundary. Total related substances are monitored by HPLC and controlled under the same ICH Q3A framework; research-grade material is not suitable because its related-substance profile may be unreported.

When tablet and capsule formulations are developed from the same API lot, particle-size control is the main variable that separates acceptable flow from line stoppage. Laser diffraction by USP 429 or ISO 13320 is used to report D10, D50, and D90; the appropriate D90 depends on whether the process is direct compression, roller compaction, or capsule tamping. A coarse, crystalline lot may flow adequately through a gravity-fed rotary tablet press but can produce low-dose content uniformity failures if the drug particle size exceeds the excipient blend capacity. Micronization is not automatically preferred because fines increase electrostatic adhesion and can reduce flow through the feed frame. Bulk density and tapped density by USP 616 are monitored to determine whether the API will require pre-blending or force-feeder assistance. Capsule filling on a dosator machine requires a different compressibility index than filling on a tamping-pin machine; the API specification should define a lot-specific particle-size window rather than a single fixed number. Published data for this specific chiral compound in high-speed capsule tamping is limited; initial formulation batches should map particle size against capsule weight variability before a commercial specification is fixed.

Assay by achiral HPLC alone is insufficient for batch release because it cannot distinguish the S-enantiomer from the R-enantiomer. The specification therefore includes an achiral purity method and a chiral identity/impurity method; the achiral method quantifies total related substances, while the chiral method quantifies the undesired enantiomer. Method robustness is evaluated under ICH Q2(R1) for specificity, linearity, accuracy, precision, and quantitation limit. The chiral method must be capable of detecting the R-enantiomer at a reporting threshold of not more than 0.05%, which is the ICH Q3A reporting threshold for a maximum daily dose below 2 g/day. For injectable product release, the method must also be compatible with the salt form and any counterion used in the formulation. The free acid is used as the reference standard; if the formulation is prepared as a sodium or meglumine salt, the sample preparation must account for the counterion mass without confusing the assay result. This dual-method control separates the Pharma Grade lot series from research-grade material, which may carry no chiral identity documentation.

What Limits Injectable Suitability for a Chiral Free Acid?

For injectable products, the free-acid batch is controlled beyond oral-grade requirements. Bacterial endotoxins are tested by USP 85 with a limit derived from the intended maximum dose; a typical endotoxin acceptance criterion for a parenteral API is calculated as K/M where K is 5 EU/kg and M is the maximum dose in mL/kg in the finished injection. The free acid may require conversion to a sodium, potassium, or meglumine salt to achieve solubility at physiological pH; the solution is subsequently buffered to a pH compatible with injection, and pH is verified by USP 791. Subvisible particulate matter is controlled by USP 788 after reconstitution or dilution; any final solution must pass the light-obscuration particle count test and the microscopic enumeration test if the product is a suspension. The API powder itself is not terminally sterilized as a dry powder; sterile filtration through a 0.22 µm membrane or terminal sterilization of the final solution is required. Bioburden is controlled to support sterilizing filtration validation; typical action limits are established under USP 61 and USP 62. Residual solvent controls for injectable use follow the same ICH Q3C limits as for oral use, but Class 1 solvents are unacceptable and should be absent; any detectable benzene must be below 2 ppm. Class 2 dichloromethane, if used in the synthetic route, is controlled at not more than 600 ppm. Elemental impurity limits are derived from ICH Q3D using the injectable route of administration; palladium from asymmetric catalysis is assigned a permissible daily exposure based on the actual dose, and transition-metal residue is measured by ICP-MS per USP 233, not inferred from residue on ignition alone.

Residual solvent retention is evaluated on each lot because solvent choice in the asymmetric synthesis strongly influences downstream formulation. The following release and formulation-fit control matrix summarises the attributes that separate the oral-grade and injectable-grade lot series.

If High-Shear Wet Granulation Is Used, Chiral Stability and Drying Endpoints Require Data Specific to the Formulation

During high-shear wet granulation, the API is exposed to moisture, binder alkalinity, and elevated temperature. The drying endpoint is defined by loss on drying USP 731 and final water content USP 921, but neither substitutes for chiral HPLC assay. If the granulating fluid contains sodium hydroxide or a basic buffer, the free acid may form a salt, altering solubility and possibly the physical state of the drug in the granule. Samples should be withdrawn at the start, middle, and end of drying to map enantiomeric purity against residual moisture. If dryer inlet air temperature is raised to reduce drying time, the outlet product temperature must remain below the temperature at which chiral drift or degradation is detected in preformulation forced-degradation studies. A fluid-bed dryer with adjustable air flow is preferred over a static tray dryer because it provides uniform moisture removal and reduces the risk of localized overheating. When a twin-screw granulator is used for continuous processing, the screw configuration and barrel temperature profile must be qualified with the API because residence time and shear energy input differ from batch granulation. Published data for this exact S-enantiomer in continuous twin-screw granulation is limited; early batches should include chiral assay at multiple barrel temperatures before the process parameter range is locked.

Granule-based sachet and dispersible tablet processing require additional weight-unit uniformity because the active is distributed across multiple granules. If the API is formulated as a granule for oral suspension, the blend should be evaluated for sedimentation, dispersity, and dose uniformity after reconstitution. The free acid may require taste-masking if the granule is intended for oral dispersible use; this is a formulation constraint, not a material deficiency. A wet granulation route is often selected to reduce segregation of the active, but the granule moisture must be dried to a level that prevents hydrolysis and microbial growth while preserving the crystalline or amorphous state. Sticking to punch faces during tablet compression is evaluated through compression force and ejection force monitoring; if sticking occurs, the lubricant type and level are adjusted rather than changing the API specification. The S-enantiomer can exhibit batch-to-batch variability in crystal habit, which affects flow and compaction; the particle-size specification is not a substitute for crystal morphology control.

Compared with the racemate and the (R)-(+)-enantiomer, the S-(-)-form is the only grade suitable for chiral drug product development where the active species is stereospecific. The racemic form cannot be substituted through a simple mass correction because the R-enantiomer becomes an uncharacterized impurity and changes the total related-substance profile. Research-grade lots of indoline-2-carboxylic acid often lack particle-size control, endotoxin testing, and residual solvent documentation; such material is not acceptable for oral commercial batch release or injectable manufacture. The Pharma Grade oral/injectable series is supported by a stability-indicating method and a retest programme based on ICH Q1A storage conditions. Handling incompatibilities include strong oxidizing agents, which can degrade the secondary amine, and prolonged storage in open containers at high relative humidity, which can increase water uptake and change flow. Compatibility with common tablet lubricants, disintegrants, and capsule shells should be confirmed because the free carboxylic acid can interact with basic excipients through salt formation or acid-base reactions. For lyophilized injection formulation, the API may be dissolved with a pH-adjusting agent; the solution should be filtered through a 0.22 µm membrane, filled into depyrogenated vials, and lyophilized under a cycle that preserves enantiomeric purity and residual moisture.